Most Recent Articles by Bryant Furlow
Interstitial lung disease appears to be a risk factor for radiation pneumonitis, a potentially life-threatening adverse effect of radiotherapy to the chest and thorax.
Radiogenomics is maturing into a predictor of patients' likelihood of experiencing radiotoxicities and late radiation effects.
Personalized medicine is changing oncology nursing. This primer explains best practices for collecting and preparing biospecimens used to guide therapy.
Psychosocial decline occurs in an estimated one-third of patients undergoing radiotherapy for cancer. These declines may sometimes be ameliorated by vigilant recognition of the need to refer patients for psychosocial support interventions.
High-dose-rate (HDR) brachytherapy is typically used as a dose-escalating boost for external beam radiotherapy for prostate cancer; however, some researchers believe it might be close to graduating to a viable monotherapy.
More Articles by Bryant Furlow
- Vitamin D and prostate cancer: Higher intake improves active surveillance outcomes
- Triple combination of two targeted therapies + immunotherapy is more effective in advanced melanoma
- Physical activity associated with less chemo-induced peripheral neuropathy
- mHealth app assesses breast cancer risk and aids prevention
- Study identifies those at high risk for developing pancreatic cancer
- Promising drug offers new paradigm for treating leukemia
- Statin use inversely linked to risk of pancreatic cancer
- Coffee may reduce risk of breast cancer recurrence
- Phase II trial shows drug combination promising in advanced melanoma
- Biennial mammography optimal screening interval for average risk women
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|